PDCD1 and melanoma: Checkpoint immunotherapy itself can also promote controlled translocation: anti-PD-1/anti-CTLA-4 regimens in mice induced movement of endogenous gut bacteria to tumor-draining lymph nodes and subcutaneous melanomas, where microbial sensing augmented antitumor T-cell responses [159].